Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

5(62.5%)

Phase 1

2(25.0%)

Phase 3

1(12.5%)

8Total

Phase 2(5)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02629419Phase 2Completed

CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis

Role: lead

NCT04031833Phase 1Completed

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)

Role: lead

NCT05541107Phase 3Unknown

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3

Role: lead

NCT04177680Phase 2Completed

Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia

Role: lead

NCT03167957Phase 2Withdrawn

Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

Role: lead

NCT03187691Phase 2Withdrawn

Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia

Role: lead

NCT03196921Phase 1Withdrawn

Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection

Role: lead

NCT02971007Phase 2Completed

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

Role: lead

All 8 trials loaded